Terremoto takes $108M series C to fuel clinical trials of AKT1 inhibitors Read more →
Bain-backed Beeline Medicines buzzes out of stealth with $300M and 5 programs from BMS Read more →
FDA official confirms plausible mechanism principles not exclusive to bespoke gene therapies Read more →
